Precision NanoSystems raises US$6 million to accelerate product innovation and global expansion
Precision NanoSystems (PNI) announced that it has closed a US$6M Series B investment. The funds will be used to expand PNI’s products and services globally and to provide a clinical manufacturing solution targeted at organizations developing precision and personalized nanomedicines. The financing round included participation from existing investors 5AM Ventures, Telegraph Hill Partners, and Rising Tide Fund.
PNI’s technology has enabled the rapid development of nanomedicines for RNA therapeutics, gene editing technologies, and other genetic medicines. Additionally, with over 200 instruments now deployed worldwide, PNI’s technology is the leading platform for the development of a broad range of small molecule, protein, and nucleic acid drug formulations. The additional financing builds on PNI’s strengths which saw rapid growth including a 70% increase in its install base in 2017. This growth culminated in 19 of the top 25 pharmaceutical companies using the NanoAssemblr™ platform and PNI’s technology being featured in over 100 peer reviewed publications.
“PNI’s NanoAssemblr technology is an enabling solution for the discovery, development and manufacture of nanomedicines. The additional capital will enable new product development and provide our growing customer base a unified solution to more efficiently develop nanomedicines at lower costs,” said Dr. James Taylor, CEO & PNI Co-Founder. Dr. Taylor further stated, “Nanomedicines are an enabling technology for the future of pharmaceuticals, including the genetic medicine revolution. PNI’s platform enables research and industrial customers worldwide access to this important technology and allows our clients to progress their drugs from bench to full scale production in a way previously unavailable in the market. Nanomedicines have the potential to direct drugs and diagnostics specifically to the site of disease thereby increasing effectiveness and reducing side effects.”
Source: https://www.prnewswire.com